Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
Gussarow D, Bonifacius A, Cossmann A, Stankov MV, Mausberg P, Tischer-Zimmermann S, Gödecke N, Kalinke U, Behrens GMN, Blasczyk R, Eiz-Vesper B. Gussarow D, et al. Among authors: tischer zimmermann s. Front Med (Lausanne). 2021 Nov 25;8:770381. doi: 10.3389/fmed.2021.770381. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34901085 Free PMC article.
Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy.
Mangare C, Tischer-Zimmermann S, Bonifacius A, Riese SB, Dragon AC, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Mangare C, et al. Among authors: tischer zimmermann s. Transfus Med Hemother. 2021 Sep 10;49(1):30-43. doi: 10.1159/000516284. eCollection 2022 Feb. Transfus Med Hemother. 2021. PMID: 35221866 Free PMC article.
Adenoviral Penton and Hexon Proteins Are Equivalent Immunogenic Targets of Virus-Specific T Cells after Hematopoietic Stem Cell Transplantation in Children.
Wintering A, Tischer-Zimmermann S, Schultze-Florey R, Beier R, Sauer M, Blasczyk R, Heim A, Eiz-Vesper B, Maecker-Kolhoff B. Wintering A, et al. Among authors: tischer zimmermann s. Transplant Cell Ther. 2023 Jun;29(6):391.e1-391.e7. doi: 10.1016/j.jtct.2023.03.013. Epub 2023 Mar 18. Transplant Cell Ther. 2023. PMID: 36934995
Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
Tischer-Zimmermann S, Bonifacius A, Santamorena MM, Mausberg P, Stoll S, Döring M, Kalinke U, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Tischer-Zimmermann S, et al. Front Immunol. 2023 Mar 24;14:878953. doi: 10.3389/fimmu.2023.878953. eCollection 2023. Front Immunol. 2023. PMID: 37033971 Free PMC article.
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.
Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, Schroers R. Mika T, et al. Front Med (Lausanne). 2019 Dec 18;6:295. doi: 10.3389/fmed.2019.00295. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31921871 Free PMC article.
18 results